BLACKROCK HEALTH SCIENCES (BME) Fundamental Analysis & Valuation
NYSE:BME • US09250W1071
Current stock price
39.32 USD
+0.61 (+1.58%)
Last:
This BME fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.
1. BME Profitability Analysis
1.1 Basic Checks
- BME had positive earnings in the past year.
- BME had a positive operating cash flow in the past year.
- BME had positive earnings in 4 of the past 5 years.
- In multiple years BME reported negative operating cash flow during the last 5 years.
1.2 Ratios
- The last Return On Invested Capital (0.24%) for BME is above the 3 year average (0.21%), which is a sign of increasing profitability.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.59% | ||
| ROE | 13.63% | ||
| ROIC | 0.24% |
ROA(3y)7.02%
ROA(5y)5.16%
ROE(3y)7.06%
ROE(5y)5.24%
ROIC(3y)0.21%
ROIC(5y)0.17%
1.3 Margins
- In the last couple of years the Profit Margin of BME has declined.
- BME's Operating Margin has improved in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 22.48% | ||
| PM (TTM) | 1000.52% | ||
| GM | 100% |
OM growth 3Y3.91%
OM growth 5Y75.67%
PM growth 3YN/A
PM growth 5Y-8.11%
GM growth 3YN/A
GM growth 5YN/A
2. BME Health Analysis
2.1 Basic Checks
- BME has about the same amout of shares outstanding than it did 1 year ago.
- Compared to 5 years ago, BME has more shares outstanding
- BME has a worse debt/assets ratio than last year.
2.2 Solvency
- BME has an Altman-Z score of 164.52. This indicates that BME is financially healthy and has little risk of bankruptcy at the moment.
- BME has a debt to FCF ratio of 0.02. This is a very positive value and a sign of high solvency as it would only need 0.02 years to pay back of all of its debts.
- BME has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
- Although BME's pure debt/equity ratio does not look good, it has limited outstanding debt compared to the Free Cash Flow. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.02 | ||
| Altman-Z | 164.52 |
ROIC/WACCN/A
WACCN/A
2.3 Liquidity
- BME has a Current Ratio of 0.23. This is a bad value and indicates that BME is not financially healthy enough and could expect problems in meeting its short term obligations.
- A Quick Ratio of 0.23 indicates that BME may have some problems paying its short term obligations.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 |
3. BME Growth Analysis
3.1 Past
- The Earnings Per Share has grown by an impressive 269.57% over the past year.
- The Earnings Per Share has been decreasing by -2.30% on average over the past years.
- Looking at the last year, BME shows a small growth in Revenue. The Revenue has grown by 2.25% in the last year.
- BME shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 8.11% yearly.
EPS 1Y (TTM)269.57%
EPS 3YN/A
EPS 5Y-2.3%
EPS Q2Q%468.64%
Revenue 1Y (TTM)2.25%
Revenue growth 3Y0.04%
Revenue growth 5Y8.11%
Sales Q2Q%7.69%
3.2 Future
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
- No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
- No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
4. BME Valuation Analysis
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 6.61 indicates a rather cheap valuation of BME.
- BME's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 26.77.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 9.24 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A
5. BME Dividend Analysis
5.1 Amount
- BME has a Yearly Dividend Yield of 7.37%, which is a nice return.
- BME's Dividend Yield is rather good when compared to the S&P500 average which is at 1.82.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.37% |
5.2 History
- The dividend of BME is nicely growing with an annual growth rate of 6.99%!
- BME has paid a dividend for at least 10 years, which is a reliable track record.
- BME has not decreased its dividend for at least 10 years, so it has a reliable track record of non decreasing dividend.
Dividend Growth(5Y)6.99%
Div Incr Years2
Div Non Decr Years11
5.3 Sustainability
- 52.94% of the earnings are spent on dividend by BME. This is a bit on the high side, but may be sustainable.
- BME's earnings are declining while the Dividend Rate has been growing. This means the dividend growth is most likely not sustainable.
DP52.94%
EPS Next 2YN/A
EPS Next 3YN/A
BME Fundamentals: All Metrics, Ratios and Statistics
NYSE:BME (4/30/2026, 8:04:00 PM)
39.32
+0.61 (+1.58%)
Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Industry StrengthN/A
Industry GrowthN/A
Earnings (Last)03-05 2026-03-05
Earnings (Next)N/A N/A
Inst Owners21.61%
Inst Owner Change-1.26%
Ins Owners0%
Ins Owner Change0%
Market Cap508.01M
Revenue(TTM)7.74M
Net Income(TTM)77.44M
Analysts0
Price TargetN/A
Short Float %0.64%
Short Ratio1.84
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 7.37% |
Yearly Dividend3.15
Dividend Growth(5Y)6.99%
DP52.94%
Div Incr Years2
Div Non Decr Years11
Ex-Date06-15 2026-06-15 (0.2621)
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 6.61 | ||
| Fwd PE | N/A | ||
| P/S | 65.63 | ||
| P/FCF | 9.24 | ||
| P/OCF | 9.24 | ||
| P/B | 0.89 | ||
| P/tB | 0.89 | ||
| EV/EBITDA | N/A |
EPS(TTM)5.95
EY15.13%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)4.26
FCFY10.83%
OCF(TTM)4.26
OCFY10.83%
SpS0.6
BVpS43.98
TBVpS43.98
PEG (NY)N/A
PEG (5Y)N/A
Graham Number76.7287 (95.14%)
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 13.59% | ||
| ROE | 13.63% | ||
| ROCE | 0.31% | ||
| ROIC | 0.24% | ||
| ROICexc | 0.24% | ||
| ROICexgc | 0.24% | ||
| OM | 22.48% | ||
| PM (TTM) | 1000.52% | ||
| GM | 100% | ||
| FCFM | 710.59% |
ROA(3y)7.02%
ROA(5y)5.16%
ROE(3y)7.06%
ROE(5y)5.24%
ROIC(3y)0.21%
ROIC(5y)0.17%
ROICexc(3y)0.21%
ROICexc(5y)0.17%
ROICexgc(3y)0.21%
ROICexgc(5y)0.17%
ROCE(3y)0.27%
ROCE(5y)0.21%
ROICexgc growth 3Y6.11%
ROICexgc growth 5Y88.89%
ROICexc growth 3Y6.11%
ROICexc growth 5Y88.89%
OM growth 3Y3.91%
OM growth 5Y75.67%
PM growth 3YN/A
PM growth 5Y-8.11%
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0.01
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0.02 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | 250 | ||
| Cash Conversion | N/A | ||
| Profit Quality | 71.02% | ||
| Current Ratio | 0.23 | ||
| Quick Ratio | 0.23 | ||
| Altman-Z | 164.52 |
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)172.8%
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)269.57%
EPS 3YN/A
EPS 5Y-2.3%
EPS Q2Q%468.64%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)2.25%
Revenue growth 3Y0.04%
Revenue growth 5Y8.11%
Sales Q2Q%7.69%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y87.1%
EBIT growth 3Y3.95%
EBIT growth 5Y89.93%
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-16.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-16.67%
OCF growth 3YN/A
OCF growth 5YN/A
BLACKROCK HEALTH SCIENCES / BME Fundamental Analysis FAQ
What is the fundamental rating for BME stock?
ChartMill assigns a fundamental rating of 3 / 10 to BME.
Can you provide the valuation status for BLACKROCK HEALTH SCIENCES?
ChartMill assigns a valuation rating of 2 / 10 to BLACKROCK HEALTH SCIENCES (BME). This can be considered as Overvalued.
Can you provide the profitability details for BLACKROCK HEALTH SCIENCES?
BLACKROCK HEALTH SCIENCES (BME) has a profitability rating of 2 / 10.
How financially healthy is BLACKROCK HEALTH SCIENCES?
The financial health rating of BLACKROCK HEALTH SCIENCES (BME) is 3 / 10.